Skip to main content

Table 2 Patient demographics at baseline, according to systemic therapy prescribed as first treatment.

From: Approaches to discontinuing efalizumab: an open-label study of therapies for managing inflammatory recurrence

 

Methotrexate (N = 20)

Cyclosporin (N = 10)

Corticosteroids (N = 8)

Combineda(N = 2)

Retinoids (N = 1)

All patients (N = 41)

Age (years)

      

Mean ± SD

49 ± 10

43 ± 12

44 ± 11

47 ± 3

41

46 ± 11

Range

28–67

20–58

20–60

45–49

-

20–67

Gender (n (%))

      

Male

13 (65.0)

5 (50.0)

5 (62.5)

1 (50.0)

1 (100)

25 (61.0)

Female

7 (35.0)

5 (50.0)

3 (37.5)

1 (50.0)

0

16 (39.0)

Ethnicity (n (%))

      

Caucasian

15 (75.0)

10 (100)

8 (100)

2 (100)

1 (100)

36 (87.8)

Asian

2 (10.0)

0

0

0

0

2 (4.9)

Other

3 (15.0)

0

0

0

0

3 (7.3)

  1. aCombined systemic corticosteroids plus methotrexate.